No abstract available (Source: Survey of Anesthesiology)

A conservative estimate suggests that over 10.2 million people are held in penal institutions throughout the world, which equates to a world prison population of 144 per 100,000 (Walmsley, 2013). Internationally, drug dependence is common amongst prison populations and many are dependent upon heroin. A systematic review of international prevalence studies of prison populations for drug dependence found prevalence rates for drug dependence to vary from 10% to 48% in male prisoners and 30% to 60% in female prisoners (Fazel et al., 2006). (Source: Drug and Alcohol Dependence)

CONCLUSIONS: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use.
PMID: 25282598 [PubMed – as supplied by publisher] (Source: Addictive Behaviors)

Abstract
SAMHSA Buprenorphine Meeting: Another Step Toward Lifting the Cap
Fraud Probe of Sober Homes Highlights Drug‐Test Scams
Bill Proposed to Provide Local Incentives to Treat Addiction
N.J. Bill Would Allow Outpatient Commitment for Addiction
California Certification: CAADAC + CAARR = CCAPP
NASADAD Issues Public Policy Statement Endorsing Naloxone
ASAM Revises Public Policy Statement on Naloxone
Methadone Patient on the Pain of Stigma
Coming up (Source: Alcoholism and Drug Abuse Weekly)

Abstract
SAMHSA Buprenorphine Meeting: Another Step Toward Lifting the Cap
Fraud Probe of Sober Homes Highlights Drug‐Test Scams
Bill Proposed to Provide Local Incentives to Treat Addiction
N.J. Bill Would Allow Outpatient Commitment for Addiction
California Certification: CAADAC + CAARR = CCAPP
NASADAD Issues Public Policy Statement Endorsing Naloxone
ASAM Revises Public Policy Statement on Naloxone
Methadone Patient on the Pain of Stigma
Coming up (Source: Alcoholism and Drug Abuse Weekly)

We examined dose and other factors associated with pain intensity among patients initiating BUP/NX for opioid use disorder. (Source: Journal of Substance Abuse Treatment)

CONCLUSION: This study is in line with some recent studies and provides further evidence that buprenorphine-naloxone is relatively safe with respect to liver injury. (Am J Addict 2013;XX:1-7).
PMID: 25251050 [PubMed – as supplied by publisher] (Source: American Journal on Addictions)

Individuals with alcohol and/or drug use disorders often fail to receive care, or evidence‐based care, yet the literature shows health economic benefits. Comparative effectiveness research is emerging that examines approved approaches in terms of real, total healthcare cost/utilization. Comprehensive retrospective insurance claims analyses are few but tend to be nationally distributed and large. The emerging pattern is that, while treatment in general is cost effective, specific therapeutics can yield different health economic outcomes. Cost/utilization data consistently show greater savings with pharmacotherapies (despite their costs) versus psychosocial treatment alone. All FDA‐approved addiction pharmacotherapies (oral naltrexone, extended‐release naltrexone, acamprosate, disulfir…

Updated Date: Sep 4, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Sep 4, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))